Investigational Drug Information for Danicopan
✉ Email this page to a colleague
What is the development status for investigational drug Danicopan?
Danicopan is an investigational drug.
There have been 24 clinical trials for Danicopan.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 16th 2022.
The most common disease conditions in clinical trials are Hemoglobinuria, Paroxysmal, Hemoglobinuria, and Glomerulonephritis, Membranoproliferative. The leading clinical trial sponsors are Alexion Pharmaceuticals, Achillion, a wholly owned subsidiary of Alexion, and Achillion Pharmaceuticals.
There are eight US patents protecting this investigational drug and one hundred and thirty-nine international patents.
Summary for Danicopan
| US Patents | 8 |
| International Patents | 139 |
| US Patent Applications | 31 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2022-05-16) |
| Vendors | 24 |
Recent Clinical Trials for Danicopan
| Title | Sponsor | Phase |
|---|---|---|
| A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH | Alexion Pharmaceuticals | Phase 3 |
| A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | Alexion Pharmaceuticals | Phase 2 |
| ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
Clinical Trial Summary for Danicopan
Top disease conditions for Danicopan
Top clinical trial sponsors for Danicopan
US Patents for Danicopan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Danicopan | ⤷ Try a Trial | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Try a Trial |
| Danicopan | ⤷ Try a Trial | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Try a Trial |
| Danicopan | ⤷ Try a Trial | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Try a Trial |
| Danicopan | ⤷ Try a Trial | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Try a Trial |
| Danicopan | ⤷ Try a Trial | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Try a Trial |
| Danicopan | ⤷ Try a Trial | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Danicopan
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Danicopan | Argentina | AR106018 | 2035-08-26 | ⤷ Try a Trial |
| Danicopan | Australia | AU2016311425 | 2035-08-26 | ⤷ Try a Trial |
| Danicopan | Australia | AU2021202728 | 2035-08-26 | ⤷ Try a Trial |
| Danicopan | Canada | CA2996415 | 2035-08-26 | ⤷ Try a Trial |
| Danicopan | China | CN108024992 | 2035-08-26 | ⤷ Try a Trial |
| Danicopan | China | CN114044800 | 2035-08-26 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
